Colo-Pro: a pilot randomised controlled trial to compare standard bolus-dosed cefuroxime prophylaxis to bolus-continuous infusion–dosed cefuroxime prophylaxis for the prevention of infections after colorectal surgery by Kirby, A et al.
ORIGINAL ARTICLE
Colo-Pro: a pilot randomised controlled trial to compare standard
bolus-dosed cefuroxime prophylaxis to bolus-continuous
infusion–dosed cefuroxime prophylaxis for the prevention of infections
after colorectal surgery
Andrew Kirby1,2 & Eduardo Asín-Prieto3,4 & Flora Agnes Burns1 & Duncan Ewin2 & Kavi Fatania1 &Mithun Kailavasan1 &
Saira Nisar1 & Agamemnon Pericleous1 & Iñaki F. Trocóniz3,4 & Dermot Burke1,2
Received: 6 August 2018 /Accepted: 13 November 2018 /Published online: 5 December 2018
# The Author(s) 2018
Abstract
Standard bolus-dosed antibiotic prophylaxis may not inhibit growth of antibiotic resistant colonic bacteria, a cause of
SSIs after colorectal surgery. An alternative strategy is continuous administration of antibiotic throughout surgery,
maintaining concentrations of antibiotics that inhibit growth of resistant bacteria. This study is a pilot comparing
bolus-continuous infusion with bolus-dosed cefuroxime prophylaxis in colorectal surgery. This is a pilot randomised
controlled trial in which participants received cefuroxime bolus-infusion (intervention arm) targeting free serum
cefuroxime concentrations of 64 mg/L, or 1.5 g cefuroxime as a bolus dose four-hourly (standard arm). Patients in both
arms received metronidazole (500 mg intravenously). Eligible participants were adults undergoing colorectal surgery
expected to last for over 2 h. Results were analysed on an intention-to-treat basis. The study was successfully piloted,
with 46% (90/196) of eligible patients recruited and 89% (80/90) of participants completing all components of the
protocol. A trialled bolus-continuous dosing regimen was successful in maintaining free serum cefuroxime concentra-
tions of 64 mg/L. No serious adverse reactions were identified. Rates of SSIs (superficial and deep SSIs) were lower in
the intervention arm than the standard treatment arm (24% (10/42) vs. 30% (13/43)), as were infection within 30 days of
operation (41% (17/43) vs 51% (22/43)) and urinary tract infections (2% (1/42) vs. 9% (4/43)). These infection rates can
be used to power future clinical trials. This study demonstrates the feasibility of cefuroxime bolus-continuous infusion of
antibiotic prophylaxis trials, and provides safety data for infusions targeting free serum cefuroxime concentrations of
64 mg/L. Trial registration: NCT02445859.
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Introduction
Colorectal surgery is a common procedure, with approximate-
ly 100,000 operations annually within England, with 18–27%
developing a surgical site infection (SSI) [1–6]. SSIs are a
major healthcare concern as they are associated with increased
morbidity, mortality, and cost [7]. In an attempt to prevent
superficial and deep SSIs, antibiotic prophylaxis is given pe-
ri-operatively, normally as a bolus dose within the hour before
surgery. Antibiotic prophylaxis is effective; when initially in-
troduced for colorectal surgery, it reduced superficial and deep
SSIs rates from 40 to 10% [8]. Recent data, however, indicate
that SSI rates have increased [2–6, 8]. A potential reason for
increased SSI rates may be suboptimal dosing of standard
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antibiotic prophylaxis, secondary to increasing rates of obesity
and growing antimicrobial resistance [9, 10]. In patients un-
dergoing colorectal surgery, one study identified that 20% of
patients were colonised with antibiot ic resistant
Enterobacteriaceae, a genus associated with approximately
80% of SSIs after colorectal surgery [11]. Furthermore, stan-
dard bolus dosing has been reported as not achieving concen-
trations believed to be effective for preventing SSIs in opera-
tions lasting longer than 2 h [12]. A potential way of improv-
ing the effectiveness of prophylaxis is by targeting antibiotic
concentrations throughout an operation at concentrations
more likely to inhibit the growth of bacteria classified as re-
sistant, by using a bolus dose of antibiotic, followed by a
continuous infusion during surgery. We therefore undertook
a pilot trial (Colo-Pro) of antibiotic prophylaxis administered
as a bolus-continuous infusion, targeting a serum concentra-
tion able to inhibit both susceptible and resistant
Enterobacteriaceae. The aims of this study were (1) to deter-
mine the feasibility of recruiting and following-up colorectal
patients in a trial comparing bolus vs. bolus-continuous infu-
sion of prophylactic cefuroxime, and (2) to determine if a
bolus-continuous dosing regimen could achieve targeted se-
rum levels of antibiotic through operations without serious
adverse reactions, and (3) to describe outcome rates in the
recruited study population.
Materials and methods
Design A pilot, randomised controlled, parallel, single-
blinded, single-centre, phase II/III trial was conducted in
which patients were allocated in a 1:1 ratio to receive either
cefuroxime bolus-infusion or standard bolus-dose antibiotic
prophylaxis before colorectal surgery. This was an external
pilot trial. All participants also received 500mg of intravenous
metronidazole. Ethical approval was obtained from the Health
Research Authority (Reference 15/YH/0260), the protocol
was reviewed by the Medical Health Research Authority
(MHRA), and the study was conducted according to Good
Clinical Practice standards with all patients providing in-
formed consent. The trial was registered at Clinical trials.
gov: NCT02445859.
Participants Patients were eligible if they were adults (≥
18 years) undergoing colorectal surgery (incision, excision,
or anastomosis of the large bowel, including anastomosis of
small to large bowel) expected to last for more than 2 h.
Patients were excluded if they were pregnant, had a cephalo-
sporin allergy or penicillin hypersensitivity, coumarin treat-
ment, concurrent use of probenecid, or a creatinine clearance
below 40 mL/min. Participants were recruited from Leeds
Teaching Hospitals NHS Trust from August 2015 to April
2017. Participants were identified and consented on their
day of surgery on admitting surgical wards. Participants were
enrolled and allocated to their intervention by research doctors
(FAB, AP, MK, KF, SN).
Randomisation Randomisation was carried out by generating
two lists of random numbers using an online sequence genera-
tor (https://www.random.org/sequences/). A person not
involved in the trial produced sealed envelopes containing
randomisation assignments. Patients were randomised prior to
surgery. Patients were blind to the allocation; however,
allocation information was known to the surgeon and
anaesthetist. Research doctors completed follow-up after
randomisation and were not blinded. Patients were randomised
in theatres. An operating surgeon confirmed that surgery should
be completed prior to the patient being randomised.
Recruitment ended when 90 patients had been randomised.
Standard dosing Intravenous (IV) cefuroxime 1.5 g bolus ad-
ministered four-hourly throughout surgery. The first dose was
given within 1 h of surgery.
Intervention dosingCefuroxime bolus-continuous dosing was
based on targeting non-protein bound (free) serum concentra-
tions of antibiotic at 64 mg/L throughout surgery. This was
intended to ensure all patients achieved and maintained serum
concentrations of at least 4 × 16 mg/L throughout surgery.
This concentration, 16 mg/L, has been reported as the
MIC90 (minimum inhibitory concentration 90 (the lowest
concentration of antibiotic at which 90% of a population
growth is inhibited)) for Enterobacteriaceae based on a clinical
study of patients undergoing colorectal surgery at Leeds
Teaching Hospitals [11]. Achieving 4 × the MIC has been
associated with maximal antimicrobial efficacy [13]. Two reg-
imens to achieve these concentrations were evaluated. One
regimen was formula-based (non-compartment model) and
the second was a population pharmacokinetic two-
compartment model (compartment model). Both models used
pharmacokinetic parameter estimates identified previously]
[12, 14]. As a safety measure, to limit overall cefuroxime
exposure, no more than 6 h of continuous infusion was ad-
ministered. In cases where the duration of surgery was longer
than 6 h, the infusion was stopped and the dosing regimen
reverted to a four-hourly bolus dose from hour 10 of surgery.
The loading dose was administered within the hour before
surgery, with initiation of the continuous infusion before sur-
gery. Further details of intervention dosing regimens are pro-
vided in Online Resource 1.
Data collection and management Creatinine clearance was
estimated for each patient using the Cockcroft–Gault equation
[15]. Data such as co-morbidities, dose and timing of
cefuroxime administration, timing of blood sample collection,
incision, and closure time were recorded prospectively.
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Sample size calculation A formal power calculation was not
required as this was a pilot study. However, to assess the
feasibility of the trial design and to obtain 60 patients with
analysable pharmacokinetic data, a recruitment target of 90
patients was set, assuming blood samples were collected from
two thirds of patients [16].
Outcomes The main outcomes in this trial are related to trial
feasibility. The main outcomes assessed are therefore recruit-
ment rates, adherence to allocated interventions, and protocol
completion rates. Protocol violations will therefore be report-
ed and described.
For the purposes of facilitating estimations of clinical out-
comes in a subsequent phase three trial, clinical outcomes
were determined. Clinical outcomes measured were the rate
of Surgical Site Infection (SSI), with superficial and deep SSIs
included, within 30 days of operation. SSI definitions were the
Centre for Disease Control’s (CDCs) National Nosocomial
Infections Surveillance (NNIS) criteria for defining SSIs [17,
18]. SSIs were formally assessed on approximately day 5 and
day 30 post-operatively by the research team. These assess-
ments were carried out in person when patients were in-
patients and by telephone using a structured questionnaire
when an outpatient [18]. All in-patient infections, organ space
SSIs, urinary tract infections, and Clostridium difficile infec-
tions within 30 days of operation (according to standard def-
initions [19]) were recorded. An outcome of infection within
30 days of surgery was assigned if a patient had any i.e. one or
more, infections diagnosed in this time period. Additionally,
days of hospitalisation within 30 days of operation and mor-
tality after operation at 30 days and 1 year were recorded.
Serious adverse reactions were defined as an event that was
serious and believed with reasonable probability to be due to
the trial treatment.
Data analysisData were assessed by an intention-to-treat anal-
ysis; patients with all outcome data missing were excluded
from analysis. In patients with incomplete outcome data, the
last observation was carried forward [20]. Additional analyses
included character isa t ion of ant ibiot ic res is tant
Enterobacteriaceae colonising the colon pre-operatively, and
a pharmacokinetic analysis of intra-operative serum
cefuroxime concentrations. The CONSORT 2010 statement:
extension to randomised pilot and feasibility trials was con-
sidered in the analysis of the data; see Online Resource 2 [21].
Microbiology sample processing Antibiotic effectiveness is
related to antibiotic concentrations in patients relative to the
susceptibility of bacteria. To determine the susceptibility of
colonic Enterobacteriaceae, which we considered to be the
most likely cause of post-operative SSIs, rectal or stoma
swabs were collected from patients pre-operatively [18].
Swabs were screened for Enterobacteriaceae resistance by
two methods: the first isolated the Enterobacteriaceae strain
that was numerically predominant, and the second isolated the
most antibiotic resistant strain. The predominant strain was
identified by inoculating a CLED agar plate with the swab,
streaking for isolated colonies, and determining the minimum
inhibitory concentration (MIC) of these colonies from the ter-
minal streak. To identify the most resistant organism, a CLED
agar plate was swabbed for confluent growth and a 30-μg
cefuroxime antibiotic disc (Oxoid) was placed in the centre.
The growth closest to the disc was cultured to purity, and
MICs were determined. MALDI-TOF and a 0.16 to 256 mg/
L cefuroxime gradient strip (biomerieux) were used to deter-
mine species and MICs respectively. Resistance was defined
as cefuroxime MIC > 8 mg/L [22].
Antibiotic serum concentration processing Blood samples
were collected intra-operatively, up to four samples per
patient throughout surgery, either via venepuncture or
via an intravascular catheter. Blood samples were stored
on ice intra-operatively, then, after centrifugation at
3000 rpm for 10 min at 5 °C. Serum was stored at −
70 °C until testing. Total serum cefuroxime concentra-
tions were measured by high-performance liquid chroma-
tography, which was performed on a Hypersil 5ODS col-
umn (HPLC Technology Ltd., Macclesfield, UK) using a
mobile phase of methanol:water:phosphoric acid (25:74:1)
and with detection by UV absorbance at 254 nm [23].
Samples were diluted 1:1 with acetonitrile, centrifuged
at 5000g and a volume of 10 μL of the supernatant
injected into the chromatograph. Quantification was by
the external standard method with intra- and inter-assay
precision (CV) below 5%.
Results
Recruitment From August 2015 to April 2017 of 262 patients
screened for study entry, 196 were eligible and 90 provided
consent. This gave a recruitment rate of 46%. Of the 90 pa-
tients providing consent, 45 were randomised to the standard
treatment group and 45 to the intervention group.
Protocol adherence There were 10 protocol violations: In the
standard treatment arm, after randomisation, two patients did
not undergo eligible colorectal surgery. In the intervention
treatment arm, after randomisation, three patients did not un-
dergo eligible colorectal surgery and two did not receive the
allocated intervention. Three patients in the intervention arm
received eligible colorectal surgery, the allocated intervention,
and hospital in-patient follow-up, but did not complete all
components of 30-day follow-up. See Online Resource 3 for
a patient flow diagram. Of the 40 patients who received the
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intervention dosing, 18 received the non-compartment model
dosing and 22 the compartment model dosing.
Baseline characteristics of randomised groups Both standard
treatment and intervention groups had comparable baseline
characteristics including: age (59 vs. 61 years), weight (78
vs 79 kg), rectal resection rate (54 vs 52%), ASA score of ≥
3 (16 vs. 21%), NNIS (National Nosocomial Infections
Surveillance risk index) scores (NNIS = 1, 60% vs. 57%),
and operation types (open surgery, 30% vs 29%) (Table 1).
Clinical outcomes Surgical site infection was found to be
present in 30% (13/43) of standard dosing treatment pa-
tients and 24% (10/42) of patients receiving the interven-
tion dosing treatment. Infection within 30 days of surgery
was detected in 51% of patients in the standard dosing
group, and in 41% of the intervention dosing group.
There was only one death, with no deaths in either group
within the 30 days after operation. Organ space infections
occurred in 5% (2/43) of patients in the
standard treatment dosing group and in 14% (6/42) of the
intervention dosing group. Urinary tract infections oc-
curred less commonly in the intervention group at 2%
(1/42) compared to the standard treatment group at 9%
(4/43). Outcomes are presented in Table 2.
Adverse reactions No serious adverse reactions were identi-
fied; specifically, no cases of Clostridium difficile infection
were identified within 30 days of surgery.
Pharmacokinetics A total of 58 patients had intra-operative
blood samples collected. Based on a protein binding of 40%,
free serum cefuroxime concentrations were determined [12].
These demonstrate that targeted concentrations of 64 mg/L
throughout surgical procedures were achieved by the
compartment-based model intervention regimen in 11/13
Table 1 Summary of patient
characteristics for per protocol
analysable patients
Standard dosing (n = 43) Intervention dosing (n = 42)
Sex Male 56% (24/43) 64% (27/42)
Age Mean, years 59 61
Weight Mean, kg 78 78
Indication for surgery Cancer 72% (31/43) 79% (33/42)
Crohn’s 14% (6/43) 7% (3/42)
Ulcerative colitis 9% (4/45) 14% (6/42)
Other 9% (4/45) 7% (3/42)
Rectal resection Yes 54% (23/43) 52% (22/42)
Chemotherapy within
12 months of surgery
Yes 23% (10/43) 21% (9/42)
Radiotherapy within
12 months of surgery
Yes 26% (11/43) 24% (10/42)
Bowel preparationa Yes 42% (18/43) 31% (13/42)
ASA 3/4/5b Yes 16% (7/43) 21% (9/42)
Operation over 3 h Yes 58% (25/43) 52% (22/42)
Charlson score Mean 2.1 2.7
Wound classification Clean contaminated 100% (43/43) 98% (41/42)
NNISc 0 33% (14/43) 33% (14/42)
1 61% (26/43) 57% (24/42)
2 7% (3/43) 5% (2/42)
3 0 5% (2/42)
Stoma formed Yes 47% (20/43) 31% (13/42)
Surgical type Laparoscopic 56% (24/43) 64% (27/42)
Open 30% (13/43) 29% (12/42)
Robotic 7% (3/43) 2% (1/42)
Lap to open 7% (3/43) 5% (2/42)
Drain inserted Yes 44% (19/43) 43% (18/42)
a Pre-operative bowel preparation = oral formulations or rectal enema
bASA = American Society of Anaesthesiologists physical status classification
c NNIS = National Nosocomial Infections Surveillance [NNIS] basic SSI risk index
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(85%) of patients. The non-compartment model maintained
higher concentrations than standard bolus dosing (Fig. 1) but
did not achieve targeted concentrations throughout surgery in
any studied patients (0/10).
Antibiotic susceptibility testing The MIC was different de-
pending upon the susceptibility test performed, with the
screen for more antibiotic resistant bacteria identifying bacte-
ria with a higher MIC50 (2 vs 1.5 mg/L) and higher MIC90
(12 vs 3 mg/L), see Table 3. There was no identified relation-
ship between MIC and outcome.
Discussion
Wehave successfully demonstrated the feasibility of performing a
trial of cefuroxime bolus-continuous infusion versus standard bo-
lus cefuroxime antibiotic prophylaxis. This conclusion is based on
a recruitment rate of 46%, which we consider good due to the
complex and multidisciplinary setting in which recruitment was
completed. In this trial, as the treatment was finished by the end of
a patient’s surgical procedure, there were no issues related to
adherence. Randomisation was successfully completed, and there
were only a limited number of patients whose surgical procedures
Table 2 Outcome measures
associated with intervention and
standard dosing regimens per
protocol analysis
Standard dosing (n = 43) Intervention dosing (n = 42)
SSI-Sa within 30 days of surgery 30% (13/43) 24% (10/42)
Infection within 30 days of surgery 51% (22/43) 41% (17/43)
Mean length of stay (days) 9.9 9.8
Death within 30 days of surgery 0% (0/43) 0% (0/42)
Death within 365 days of surgery 2% 1/43 0% 0/42)
SSI-Ob within 30 days of surgery 5% (2/43) 14% (6/42)
UTIc within 30 days of surgery 9% (4/43) 2% (1/42)
a SSI-S: superficial surgical site infection
b SSI-O: organ space surgical site infection
c UTI: urinary tract infection
Fig. 1 Free serum cefuroxime
concentrations for 58 patients
according to intervention
treatment (compartment and non-
compartment) and standard
treatment dosing regimens.
Horizontal lines represent 64 mg/
L and 16 mg/L
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were not carried out. Future studies should aim to randomise at
the last available opportunity, and confirm surgical procedures
with the most senior member of the surgical team. The single
blinding used in the trial was successfully piloted, but future
studies should aim to also blind the patients’ clinical teams as
well as outcome assessors. There were occasions when a safety
concern in relation to low body weight and reduced renal func-
tion resulted in non-allocated antibiotic prophylaxis being admin-
istered. Guidance within the protocol related to these specific
issues could prevent these protocol violations.
In assessing the intervention bolus-continuous dosing regi-
mens, the compartment model–based dosing regimen, which
was adjusted for renal function, was the more effective model
and achieved target concentrations in > 80% of patients as pre-
dicted. This compartment based–dosing regimen is therefore
suitable to be used in a clinical trial targeting free serum concen-
trations of 64m/L of cefuroxime. The demonstrated feasibility of
this trial is important, as it has been shown that antibiotic con-
centrations at both the start and the end of surgery are important
predictors of clinical effectiveness [24]. The bolus-continuous
infusion approach to prophylaxis is a strategy that can achieve
desired concentrations of antibiotic throughout surgery, including
the end of surgery, across multiple surgical procedures, and for
multiple antibiotics, making the bolus-continuous infusion ap-
proach highly generalisable.
Rates of SSIs (superficial and deep SSIs) were lower in the
intervention group, as were any infections and rates of urinary
tract infection. These lower rates are consistent with the aim of
the intervention, which is to reduce post-operative infections. As
the difference in any infection between intervention groups was
higher than the difference between SSIs, infection within 30 days
of operation may be considered as the optimal outcome measure
in future trials. This approach is supported by previous data that
show that antibiotics with a long half-life e.g. ceftriaxone, which
act like a continuous infusion of a short half-life antibiotic e.g.
cefuroxime, reduce post-operative respiratory tract, surgical site,
and urinary tract infections [25]. However, these long half-life
antibiotics are currently avoided in clinical practice over concerns
relating to increased risks of Clostridium difficile infection. All
three patients lost-to follow-up at day 30 had an infection iden-
tified before their day 30 review. A future study could therefore
consider using an intention-to-treat analysis with Bthe last obser-
vation carried forward^ method to deal with this as done in this
study analysis, or could consider including an outcome measure
assessment after a shorter time period e.g. 14 days.
The rate of organ space surgical site infection was higher in
the intervention group. Considering known rates of organ
space infection it is likely this reflects a lower than expected
rate of these events in the standard treatment group [2].
Alternatively, it has been suggested that antibiotics have the
potential to select for bacteria with collagenase activity, with
the ability to cause anastomotic leak [26]. Higher doses of
antibiotic associated with the intervention treatment could
therefore be consistent with increased selective pressure on
the bacteria, and so increased anastomotic leak and subse-
quent organ space infection. No mortality was seen in the
30 days after the intervention in either treatment group.
The compartment model intervention was successful in
obtaining serum concentrations targeted at 64 mg/L for the
duration of surgery. This study was performed on a population
of patients with high rates of cefuroxime susceptible
Enterobacteriaceae colonisation of the colon, with resistance
detected in 3–11% of patients, depending on the method of
resistance detection used. It is possible that the effectiveness
of the intervention may be dependent upon the rate/
characteristics of Enterobacteriaceae resistance.
In summary, completion of this feasibility study suggests
that a large pragmatic trial into bolus-continuous infusion of
cefuroxime prophylaxis can be completed. As rates of antibi-
otic resistance increase the need for such trials is becoming
more urgent.
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